I was very surprised by the letter “Efficacy but not effectiveness of sublingual immunotherapy for grass pollen allergy: time to avoid waste in health care expenditure” by Corrao et al. published in the European Journal of Internal Medicine [1]. In fact, the statements by the authors on sublingual immunotherapy (SLIT) have no ground. They, based on a recent negative meta-analysis on grass pollen SLIT tablets for seasonal rhinitis published by the other two authors of this letter [2], in the final paragraph state that “patients should be informed about the low a priori chances of clinical improvement”.
